Transcatheter aortic-valve replacement with a self-expanding prosthesis.

N Engl J Med

From Mount Sinai Medical Center, New York (D.H.A.), and St. Francis Hospital, Roslyn (N.R., G.P.) - both in New York; Beth Israel Deaconess Medical Center, Boston (J.J.P.); Houston Methodist DeBakey Heart and Vascular Center (M.J.R., N.S.K.), and Texas Heart Institute at St. Luke's Medical Center (J.S.C.) - both in Houston; Riverside Methodist Hospital, Columbus, OH (S.J.Y.); University of Michigan Medical Center, Ann Arbor (G.M.D., S. Chetcuti), and Spectrum Health Hospitals, Grand Rapids (J.H., W.M.) - both in Michigan; University of Pittsburgh Medical Center, Pittsburgh (T.G.G.); Palo Alto Veterans Affairs Medical Center, Palo Alto, CA (M.B.); St. Vincent Medical Center, Indianapolis (J.H.); University of Kansas Hospital, Kansas City (G.Z., P.T.); Duke University Medical Center, Durham, NC (G.C.H., J.K.H.); Johns Hopkins Hospital, Baltimore (J.C.); Pinnacle Health, Harrisburg, PA (B.M., M.M.); and Medtronic, Minneapolis (S. Chenoweth), and Mayo Clinical Foundation, Rochester (J.K.O.) - both in Minnesota.

Published: May 2014

Background: We compared transcatheter aortic-valve replacement (TAVR), using a self-expanding transcatheter aortic-valve bioprosthesis, with surgical aortic-valve replacement in patients with severe aortic stenosis and an increased risk of death during surgery.

Methods: We recruited patients with severe aortic stenosis who were at increased surgical risk as determined by the heart team at each study center. Risk assessment included the Society of Thoracic Surgeons Predictor Risk of Mortality estimate and consideration of other key risk factors. Eligible patients were randomly assigned in a 1:1 ratio to TAVR with the self-expanding transcatheter valve (TAVR group) or to surgical aortic-valve replacement (surgical group). The primary end point was the rate of death from any cause at 1 year, evaluated with the use of both noninferiority and superiority testing.

Results: A total of 795 patients underwent randomization at 45 centers in the United States. In the as-treated analysis, the rate of death from any cause at 1 year was significantly lower in the TAVR group than in the surgical group (14.2% vs. 19.1%), with an absolute reduction in risk of 4.9 percentage points (upper boundary of the 95% confidence interval, -0.4; P<0.001 for noninferiority; P = 0.04 for superiority). The results were similar in the intention-to-treat analysis. In a hierarchical testing procedure, TAVR was noninferior with respect to echocardiographic indexes of valve stenosis, functional status, and quality of life. Exploratory analyses suggested a reduction in the rate of major adverse cardiovascular and cerebrovascular events and no increase in the risk of stroke.

Conclusions: In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aortic-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aortic-valve replacement. (Funded by Medtronic; U.S. CoreValve High Risk Study ClinicalTrials.gov number, NCT01240902.).

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1400590DOI Listing

Publication Analysis

Top Keywords

aortic-valve replacement
16
transcatheter aortic-valve
12
tavr self-expanding
8
self-expanding transcatheter
8
surgical aortic-valve
8
patients severe
8
severe aortic
8
aortic stenosis
8
stenosis increased
8
tavr group
8

Similar Publications

Background: Repair of the regurgitant bicuspid aortic valve is an attractive alternative to valve replacement. Although good long-term outcomes have been reported, postoperative aortic stenosis remains a major late cause of repair failure in bicuspid aortic valves. Sinus plication is effective for creating a more symmetrical commissural angle, leading to a decrease in the mean transvalvular pressure gradient.

View Article and Find Full Text PDF

Background: Transcatheter closure of percutaneous paravalvular leak (PVL) is a technically challenging procedure, especially after surgical mechanical valve replacements (SMVR), as the risk of interference with the prosthetic valve discs and the complex interventional techniques required for mitral PVL closure. Our study was designed to review the results with transcatheter closure of PVL after SMVR.

Methods: From January 2018 through December 2023, a total of 64 patients with PVL after SMVR underwent transcatheter closure with the help of preoperative 3-dimensional printing model and simulator for image evaluation.

View Article and Find Full Text PDF

Analysis of the haemodynamic changes caused by surgical and transcatheter aortic valve replacements by means fluid-structure interaction simulations.

Comput Biol Med

January 2025

UCL Mechanical Engineering, University College London, UK; Ri.MED Foundation, Palermo, Italy; University of Palermo, Department of Engineering, Palermo, Italy. Electronic address:

Aortic valve replacements, both surgical and transcatheter, are nowadays widely employed treatments. Although clinically effective, these procedures are correlated with potentially severe clinical complications which can be associated with the non-physiological haemodynamics that they establish. In this work, the fluid dynamics changes produced by surgical and transcatheter aortic valve replacements are analysed and compared with an ideal healthy native valve configuration, employing advanced fluid-structure interaction (FSI) simulations.

View Article and Find Full Text PDF

Transcatheter aortic valve repair (TAVR) presents a minimally invasive alternative to traditional surgical valve replacement, albeit not without its own set of complications. A rare complication is the infolding of the self-expanding valve, which can precipitate cardiac arrest. The estimated incidence rate of this complication stands at 1.

View Article and Find Full Text PDF

Transcatheter aortic valve replacement (TAVR) has become a viable treatment option for patients with severe aortic stenosis among all risk subsets. As TAVR use becomes more prevalent and patients live longer with their transcatheter valve, an increasing number of these patients can be expected to present with ACS. Overall, there is a paucity of high-quality data detailing incidence, pathophysiology, and management of ACS in this subset.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!